Achema middle east

Press Releases

Optibrium secures multi-million-pound financing package from Shawbrook to accelerate business growth

Proceeds will accelerate Optibrium’s product development and expand the global reach of its computational chemistry and AI-driven discovery technology.  CAMBRIDGE, UK, 08 July 2025 – Optibrium, a leading developer of software and AI solutions for molecular design, today announced it has...

Aptar CSP Technologies’ Dual-Active Material Science Technology Simultaneously Controls Moisture and Oxygen for Pharmaceutical Drugs and Medical Devices

Dual-active material science solution is ideal for sensitive formulations Auburn, AL, July 8, 2025 – Aptar CSP Technologies, part of AptarGroup, Inc. and a leader in active material science, today announced that it has developed a dual-active material science technology...

datma Launches Federated Biomarker Explorer with Free Access to Help Pharma Validate Real-World Data Coverage

Pharma teams can now assess biomarker coverage across datma's federated network with no cost, contracts, or IT support required. datma, a leader in federated real-world data access, today announced the launch of the Federated Biomarker Explorer, a new application that allows...

Infudopa SubC Parkinsons Therapy: Neuraxpharm-Dizlin Deal

Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company dedicated to central nervous system (CNS) disorders, and Dizlin Pharmaceuticals AB (“Dizlin”), a Swedish R&D company focused on late-stage Parkinsons disease (PD), today announced a strategic global co-development agreement for...

HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

Haleon today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025. This appointment follows Franck Riot deciding to leave Haleon after six years in the business. Carl joins Haleon from...

Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines

London, 28 June 2025 – In its ongoing mission to help meet America’s growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D...

API China 2025 Concludes with Strong Turnout and Industry-Wide Momentum

Asia’s leading pharma show draws 200,000 visits and nearly 4,000 exhibitors across three co-located events in Guangzhou Beijing, The 92nd edition of API China successfully wrapped up on 23 May, reaffirming its role as a cornerstone event for the pharmaceutical, health, and nutrition...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »